uniQure N.V. (36)

Browse by Contract Category

Contracts

Lease Agreement relating to 91 Hartwell Avenue, Lexington, Massachusetts, dated as of February 1, 2022, by and between uniQure Inc. and NRL 91 Hartwell LLC (Filed With SEC on February 25, 2022)
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 25, 2022)
Third Amended and Restated Loan and Security Agreement as of December 15, 2021, by and among uniQure biopharma B.V., uniQure Inc., uniQure IP B.V., the Company and Hercules... (Filed With SEC on February 25, 2022)
Form of Performance Stock Unit Award, effective December 8, 2021 under the 2014 Share Incentive Plan (Filed With SEC on February 25, 2022)
Cooperation Agreement, dated as of April 16, 2021, by and among uniQure N.V., ForUniqure B.V., Forbion 1 Management B.V., Forbion International Management B.V., and Forbion... (Filed With SEC on May 10, 2021)
Lease Agreement relating to 20 Maguire Road, Lexington, Massachusetts, dated as of December 22, 2021, by and between uniQure Inc. and G&I IX/GP4 20 Maguire LLC (Filed With SEC on February 25, 2022)
Form of Restricted Stock Unit Award, effective December 8, 2021, under the 2014 Share Incentive Plan (Filed With SEC on February 25, 2022)
Form of Share Option Agreement, effective December 8, 2021, under the 2014 Share Incentive Plan (Filed With SEC on February 25, 2022)
Consent and Amendment No. 3 to Second Amended and Restated Loan and Security Agreement, dated July 30, 2021, by and among the Registrant, Hercules Capital Inc., and the other... (Filed With SEC on October 25, 2021)
tAmended and Restated Employment Agreement, effective June 15, 2021, by and between uniQure biopharma B.V. and Christian Klemt (Filed With SEC on July 26, 2021)
t Equity Side Letter, effective May 17, 2021, by and between uniQure N.V. and Pierre Caloz (Filed With SEC on July 26, 2021)
t Employment Agreement, effective May 17, 2021, by and between uniQure biopharma B.V. and Pierre Caloz (Filed With SEC on July 26, 2021)
t2014 Share Incentive Plan, Amended and Restated, effective as of June 16, 2021 (Filed With SEC on July 26, 2021)
Sale and Purchase Agreement, executed June 21, 2021, by and between uniQure N.V. and Corlieve Therapeutics SAS (Filed With SEC on July 26, 2021)
Sales Agreement dated March 1, 2021 by and between uniQure N.V. and SVB Leerink LLC (Filed With SEC on March 2, 2021)
Amendment to Collaboration and License Agreement by and between uniQure Biopharma B.V. and Bristol-Myers Squibb Company dated December 1, 2020 (Filed With SEC on March 1, 2021)
Amendment No. 2 to Second Amended and Restated Loan and Security Agreement as of January 29, 2021 by and among uniQure Biopharma B.V., uniQure, Inc., uniQure IP B.V., the Company... (Filed With SEC on March 1, 2021)
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 1, 2021)
Separation agreement, executed August 25, 2020, by and between uniQure Inc. and Robert Gut (Filed With SEC on October 27, 2020)
Separation agreement, executed August 25, 2020, by and between uniQure biopharma B.V. and Sander van Deventer (Filed With SEC on October 27, 2020)
103* Employment agreement, executed September 14, 2020, by and between uniQure Inc. and Ricardo Dolmetsch (Filed With SEC on October 27, 2020)
Amended and Restated Employment Agreement, executed March 1, 2020 by and between uniQure Inc. and Dr. Robert Gut (Filed With SEC on March 2, 2020)
Sales Agreement dated March 2, 2020 by and between uniQure N.V. and SVB Leerink LLC (Filed With SEC on March 2, 2020)
Amended and Restated Employment Agreement, executed March 1, 2020 by and between uniQure Inc. and Jonathan Garen (Filed With SEC on March 2, 2020)
Amended and Restated Employment Agreement, executed March 1, 2020 by and between uniQure Inc. and Maria Cantor (Filed With SEC on March 2, 2020)
Amended and Restated Employment Agreement, executed March 1, 2020 by and between uniQure biopharma B.V. and Christian Klemt (Filed With SEC on March 2, 2020)
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 2, 2020)
Collaboration and License Agreement by and between 4D Molecular Therapeutics, Inc and uniQure biopharma B.V., dated August 6, 2019 (Filed With SEC on October 28, 2019)
Amended and Restated Collaboration Agreement by and between 4D Molecular Therapeutics, Inc and uniQure biopharma B.V., dated August 6, 2019 (Filed With SEC on October 28, 2019)
Separation Agreement, executed September 16, 2019, by and between the Company and Dr. Scott McMillan (Filed With SEC on September 20, 2019)
Employment Agreement, executed September 17, 2019, by and between the Company and Dr. Sander van Deventer (Filed With SEC on September 20, 2019)
Amended and Restated Employment Agreement, executed September 17, 2019, by and between the Company and Dr. Kuta (Filed With SEC on September 20, 2019)
Underwriting Agreement between the Company, Goldman Sachs & Co. LLC and SVB Leerink LLC, as representatives for the underwriters named therein, dated as of September 5, 2019 (Filed With SEC on September 6, 2019)
Second Amendment Lease relating to 113 Hartwell Avenue, Lexington Massachusetts, dated as of June 17, 2019, by and between the Company and King 113 Hartwell LLC (Filed With SEC on July 29, 2019)
Form of Share Option Agreement, effective June 18, 2019, under the 2014 Share Incentive Plan (Filed With SEC on July 29, 2019)
Employment Agreement dated August 20, 2018 by and between uniQure, Inc. and Dr. Robert Gut (Filed With SEC on February 28, 2019)